

Press release

Lund 19 September 2022

Scandinavian ChemoTech's IQwave™ used to treat pancreatic cancer at Ulis hospital in Ukraine

A team of oncology experts led by Professors Vladimir Klimenko and Alexey Kovalev has reported that they have now performed the first Tumour Specific Electroporation™ (TSE) treatment on pancreatic cancer through an open surgical procedure, at Ulis Hospital in Ukraine.

The team of experts that performed the treatment has previously been credited for having performed the first liver transplant in Ukraine and are highly skilled and research-oriented.

The patient in question is a 60-year-old woman with ductal carcinoma of the pancreatic head, who had received conventional chemotherapy with limited response. The tumour was deemed unresectable and TSE treatment with IQwave under open surgical procedure was chosen as an alternative, after due ethical and administrative approvals.

In the report that has been shared with ChemoTech, Klimenko and Kovalev state that the patient has restored normal functions and tolerated the treatment well. The team has also interestingly reported that the pathological response is very impressive. With the initial pathological response, the experts at Ulis are optimistic about a favourable outcome and survival rate.

Professor Vladimir Klimenko, Head of the Department of Surgery at Zaporozhye Medical University stated - *"I was lucky, together with Professor Alexei Kovalev with whom I have been associated for many years of professional work, to perform the first TSE therapy operation in Ukraine on a patient with cancer of the head of the pancreas.*

"Having extensive experience in pancreatoduodenal surgery, I was amazed by the ease of implementation and the effectiveness of this procedure. From a technical point of view, it does not present a problem for any surgeon trained in this anatomical area. I want to note the mild course of the postoperative period, but most importantly, the amazing pathological changes in the form of almost complete pathomorphosis (change of disease) that occurred in the tumour tissue within only two hours after the TSE therapy. I am sure that TSE therapy will take its rightful place in the arsenal of methods for treating cancer of various localizations, especially in the treatment of pancreatic tumours. Possible indications in this area I see are neoadjuvant regimen for locally advanced conditionally resectable pancreatic cancers and a palliative regimen for metastatic unresectable tumours. Together with Professor Alexei Kovalev, we intend to continue working in this direction."

"We are very happy with the safety procedure conduction and the initial pathology results of the pancreatic cancer case at Ulis hospital. As persistent as pancreatic cancer cells are in resisting current treatments, as committed are we here at ChemoTech to finding new paths

where the TSE technology can address this unmet medical need.” - says Dr Suhail Mufti, Medical Advisor at Scandinavian ChemoTech.

“Even if it’s impossible to predict the end result of this treatment it feels great to hear that our TSE technology performed as expected and without any complications. Our initial target was to start treating the first pancreatic patients earliest by the end of 2023 or 2024. ChemoTech will now need to re-write our clinical strategy two years ahead of schedule.” -says Mohan Frick CEO and Co-Founder

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00
ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,
E-mail: certifiedadviser@penser.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-09-2022 21:30 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.